Who is BlueRock?
BlueRock Therapeutics LP is a clinical stage cell therapy harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Two of our novel investigational cell therapies, bemdaneprocel (BRT-DA01) for the treatment of Parkinson’s disease and OpCT-001 for the treatment of primary photoreceptor diseases are clinical stage programs. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves.
What Are We Doing?
Our foundational science harnesses the ability to create and then direct the differentiation of universal pluripotent stem cells into authentic, functional cells that can be used as allogeneic cellular therapies to treat a broad array of diseases. We can also further engineer these cells, enabling them to produce enzymes, antibodies, and other proteins for additional therapeutic benefit.
We are passionate about delivering on the promise of cellular and gene therapy, shaping the future of cellular medicine, and delivering new therapies to millions of patients with treatment options.
We are seeking individuals who are collaborative, thrive in a fun and dynamic culture, and are steadfast in the commitment to advance cutting-edge cellular therapies to impact patients’ lives.
The Myeloid Platform team is developing next‑generation microglia‑based therapeutics for neurodegenerative and neuroinflammatory diseases. The Myeloid Platform Co-Op is responsible for the development of complex in vitro model of neurodegenerative diseases to further BlueRock’s drug development pipeline. This role places the co‑op at the center of cutting‑edge research involving human iPSC‑derived microglia, neural co‑culture systems, and translational assay development. The successful candidate will act as part of the Myeloid platform team and will collaborate with other groups such as Discovery Analytics and Bioinformatics to generate sound scientific evidence to support and drive the company’s preclinical pipeline.
ResponsibilitiesDevelop protocols for in vitro disease modelling of neurodegenerative disorders utilizing iPSC-based modelsGeneration, expansion, and analysis of neural organoids and 3D microglia–neuron spheroids.Perform differentiation, maintenance, and phenotypic characterization of iPSC‑derived microglia, macrophages, and related myeloid lineages. Maintain cultures with strict aseptic technique and robust documentation.Support experimental pipelines that evaluate microglial responses in neurodegenerative contexts.Analyze data, prepare summaries, and present findings to the Myeloid Platform team.Analyze and document experimental data in electronic laboratory notebooks in a timely and accurate manner, in accordance with the company quality management system.This position requires excellent communication skillsThis position requires on-site presence at least 5 days per week with occasional work on weekends and after hours.Qualifications & RequirementsHave (Currently enrolled in a degree program at an accredited college or university developmental biology, neuroscience, stem cell biology or related discipline). Possess the (Ability to work a 12 month assignment, full-time). Must be 18 years of age by the start of the internship/co-op. Must have transportation to the site in New York, NY, US. This position is intended to be on-site and candidates will be informed should anything change. Excellent organizational skills, sufficient to multi-task in an extremely fast-paced environment with changing priorities. Ability to work independently while contributing to collaborative project goals.Enthusiasm for learning new experimental techniques and contributing to platform‑level innovation.Strongly preferred hands‑on experience generating or working with neural organoids or other 3D culture systems.Background in microglia biology, macrophage biology, or myeloid differentiation.Strong proficiency in aseptic technique, mammalian cell culture, and experience with primary cells or iPSC‑derived cultures.Demonstrated ability to independently execute and troubleshoot experiments.BlueRock Therapeutics Company Culture Highlights
Winner of Boston Business Journal's Best Places to Work (Mid-size Company) 2023
Winner of Comparably's Award for Best Company for Diversity 2022
Winner of Comparably's Award for Best Company for Women 2022
Winner of Comparably's Award for Best CEO 2022
BlueRock Therapeutics is ranked in the top 5% of companies for Overall Culture on Comparably.
Engineering Department is ranked in the top 5% of companies for Overall Culture on Comparably.
Follow us on Linkedin: https://www.linkedin.com/company/bluerocktx/
Equal Opportunity Workplace: At BlueRock, we welcome and support differences and diversity and we are proud to be an equal opportunity workplace. Please let us know if you require disability-related accommodation or other grounds protected by human rights legislation during the recruitment process so that we can work with you to meet your needs.
